产品展示
Arry-380
点击次数:243发布时间:2013/4/2 15:10:14
更新日期:2022/8/19 17:45:40
所 在 地:中国大陆
产品型号:
优质供应
详细内容
Arry-380
上海义森生物科技有限公司
技术数据:
分子量(MW): 569.63 化学式: C29H27N7O4S
溶解度: DMSO 114mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ CAS号: 937265-83-3
生物活性
ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase HER2 and p95-HER2 inhibitor with an IC50 of 8 and 7 nM, respectively. [1] However, ARRY-380 inhibits EGFR with an IC50 of 4 μM. ARRY-380 is about 500-fold selective for HER2 versus EGFR. [1] ARRY-380 produces significantly antitumor activities in multiple HER2-dependent tumor xenograft models and generates additive activity in combination with standard-of-care agents. [1] ARRY-380 is in a phase I clinical trial for the treatment of breast cancer. [2]
技术数据:
分子量(MW): 569.63 化学式: C29H27N7O4S
溶解度: DMSO 114mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ CAS号: 937265-83-3
生物活性
ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase HER2 and p95-HER2 inhibitor with an IC50 of 8 and 7 nM, respectively. [1] However, ARRY-380 inhibits EGFR with an IC50 of 4 μM. ARRY-380 is about 500-fold selective for HER2 versus EGFR. [1] ARRY-380 produces significantly antitumor activities in multiple HER2-dependent tumor xenograft models and generates additive activity in combination with standard-of-care agents. [1] ARRY-380 is in a phase I clinical trial for the treatment of breast cancer. [2]
技术数据:
分子量(MW): 569.63 化学式: C29H27N7O4S
溶解度: DMSO 114mg/mL Water <1mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ CAS号: 937265-83-3
生物活性
ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase HER2 and p95-HER2 inhibitor with an IC50 of 8 and 7 nM, respectively. [1] However, ARRY-380 inhibits EGFR with an IC50 of 4 μM. ARRY-380 is about 500-fold selective for HER2 versus EGFR. [1] ARRY-380 produces significantly antitumor activities in multiple HER2-dependent tumor xenograft models and generates additive activity in combination with standard-of-care agents. [1] ARRY-380 is in a phase I clinical trial for the treatment of breast cancer. [2]
技术数据:
分子量(MW): | 569.63 | |
---|---|---|
化学式: | C29H27N7O4S | |
溶解度: | DMSO 114mg/mL Water <1mg/mL Ethanol <1mg/mL | |
纯度: | >99% | |
稳定性: | at -20℃ | |
CAS号: | 937265-83-3 |
生物活性
ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase HER2 and p95-HER2 inhibitor with an IC50 of 8 and 7 nM, respectively. [1] However, ARRY-380 inhibits EGFR with an IC50 of 4 μM. ARRY-380 is about 500-fold selective for HER2 versus EGFR. [1] ARRY-380 produces significantly antitumor activities in multiple HER2-dependent tumor xenograft models and generates additive activity in combination with standard-of-care agents. [1] ARRY-380 is in a phase I clinical trial for the treatment of breast cancer. [2]